Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levomilnacipran ER vs Duloxetine in MDD
NCT07253207Phase 3Completed
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levomilnacipran in major depressive disorder (MDD), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Started Oct 2024; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07253207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253207.